ReviewJournal of translational medicine2019
Integrating omics for a better understanding of Inflammatory Bowel Disease: a step towards personalized medicine.
Review in Journal of translational medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pharmacogenetics in Response to Biological Agents in Inflammatory Bowel Disease: A Systematic Review.International journal of molecular sciences · 2025Pooled it
- Review
- Multi-omics feature engineering driven by biomedical foundation models improves drug response prediction for inflammatory bowel disease patients.Scientific reports · 2026Article
- Translational approaches in microbiome research: from functional mechanisms to next-generation therapeutics.Frontiers in microbiology · 2026Review
- A decade of clinical data with vedolizumab: the past, present, and future.Therapeutic advances in gastroenterology · 2026Review
- Prevalence and indoor environment risk factors of parent-reported food allergy symptoms among preschool children in Haikou City, China: a cross-sectional survey.Frontiers in public health · 2026Article
- Decoding the power of the microbiome in human health.Frontiers in cellular and infection microbiology · 2026Review
- From AI-AssistedPharmaceuticals (Basel, Switzerland) · 2025Review
- Integrated multi-omics of feces, plasma and urine can describe and differentiate pediatric active Crohn's Disease from remission.Communications medicine · 2025Article
- Deep representation learning for clustering longitudinal survival data from electronic health records.Nature communications · 2025Article
- Using metabolomics to investigate the relationship between the metabolomic profile of the intestinal microbiota derivatives and mental disorders in inflammatory bowel diseases: a narrative review.Research in pharmaceutical sciences · 2025Review
- Predictive biomarkers for anti-TNF alpha therapy in IBD patients.Journal of translational medicine · 2024Review
- Identifying Dental Pulp Stem Cell as a Novel Therapeutic trategy for Digestive Diseases.Current stem cell research & therapy · 2024Review
- Review
- Article
- Acceptability Criteria of Precision Medicine: Lessons From Patients' Experiences With the GUIDE-IBD Trial Regarding the Use of Mobile Health Technology.Crohn's & colitis 360 · 2023Article
- Microbial Dysbiosis Tunes the Immune Response Towards Allergic Disease Outcomes.Clinical reviews in allergy & immunology · 2023Review
- Article
- Immunomodulatory Mechanism and Potential Application of Dental Pulp-Derived Stem Cells in Immune-Mediated Diseases.International journal of molecular sciences · 2023Review
- Computational Simulation Model to Predict Behavior Changes in Inflammatory Bowel Disease Patients during the COVID-19 Pandemic: Analysis of Two Regional Japanese Populations.Journal of clinical medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInflammatory Bowel Disease (IBD) is a multifactorial chronic disease. Understanding only one aspect of IBD pathogenesis does not reflect the complex nature of IBD nor will it improve its clinical management. Therefore, it is vital to dissect the interactions between the different players in IBD pathogenesis in order to understand the biology of the disease and enhance its clinical outcomes.
aimsTo provide an overview of the available omics data used to assess the potential mechanisms through which various players are contributing to IBD pathogenesis and propose a precision medicine model to fill the current knowledge gap in IBD.
resultsSeveral studies have reported microbial dysbiosis, immune and metabolic dysregulation in IBD patients, however, this data is not sufficient to create signatures that can differentiate between the disease subtypes or between disease relapse and remission.
conclusionsWe summarized the current knowledge in the application of omics in IBD patients, and we showed that the current knowledge gap in IBD hinders the improvements of clinical decision for treatment as well as the prediction of disease relapse. We propose one way to fill this gap by implementing integrative analysis of various omics datasets generated from one patient at a single time point.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.